Duyuru • Apr 23
Grey Matters Health Inc. announced that it expects to receive CAD 1 million in funding Grey Matters Health Inc. announced a non-brokered private placement to issue 2,500,000 units at an issue price of CAD 0.40 for the proceeds of CAD 1,000,000 on April 22, 2026. Each unit will consist of one Class A common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder to acquire one common share at an exercise price of CAD 0.60 per warrant share for a period of 24 months from the issuance date. The offering is expected to close in tranches on or before May 21, 2026.The company may pay cash finders' fees and finder warrants to eligible finders, up to 8 per cent of the proceeds raised and units issued for investors introduced to the company by the eligible finders. Securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities legislation. Duyuru • Jan 02
Algernon Health Inc. announced that it has received CAD 0.857014 million in funding from American Molecular Imaging and other investors. On December 31, 2025, the Algernon Health Inc. closed the transaction by issuing 1,678,586 units at an issue price of CAD 0.07 for the proceeds of CAD 117,501 under fourth and final tranche. Certain insiders of the Company participated in the Fourth Tranche of the Offering in the amount of CAD 32,501. The Company did not pay any cash finder’s fees pertaining to the Fourth Tranche of the
Offering Duyuru • Nov 07
Algernon Health Inc. announced that it expects to receive CAD 0.5 million in funding Algernon Health Inc. announced a non-brokered private placement of 7,142,857 Units of the company at a price per share of CAD 0.07 for gross proceeds of CAD 500,000 on November 6, 2025. Each Unit will consist of one Class A common share in the capital of the Company and one-half Common Share purchase warrant. Each full Common Warrant will entitle the holder to acquire one Common Share at an exercise price of CAD 0.15 per Common Warrant Share for a period of twelve months from the issuance date. The Offering is expected to close in tranches on or before November 30, 2025. Duyuru • Jul 25
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.761 million in funding On July 24, 2025, Algernon Pharmaceuticals Inc closed the transaction. The company announced that it has issued 233,333 subscription receipts at an issue price of CAD 0.60 per receipt for gross proceeds of CAD 139,999.8 in second and final tranche. Certain insiders of the Company participated in the Offering in the amount of CAD 90,000. The Company did not pay any cash finder’s fees pertaining to the Second Tranche of the Offering. The Company is also announcing that the Offering is now closed. The securities issued and issuable, described in this and the previous news releases on May 27, 2025 and June 30, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. Duyuru • Jul 17
Algernon Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2025 Algernon Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2025. Duyuru • May 27
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding Algernon Pharmaceuticals Inc. announced a non-brokered private placement of common units at a price of CAD 0.07 per unit and preferred units at a price of CAD 0.7 per unit for the gross proceeds of CAD 1,000.000 on May 27, 2025. Each common unit will consist of one Class A common share in the capital of the company and one-half common share purchase warrant. Each full Common Warrant will entitle the holder to acquire one common share at an exercise price of CAD 0.15 per common warrant share. Each preferred unit will consist of one preferred share in the capital of the company and one half preferred share purchase warrant. Each full preferred warrant will entitle the holder to acquire one preferred share at an exercise price of CAD 1.50 per preferred warrant share until the Expiry Date, subject to acceleration of the expiry date as described below. The Offering is expected to close in tranches on or before June 30, 2025. The securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. Duyuru • May 23
Algernon Pharmaceuticals Inc. (CNSX:AGN) completed the acquisition of NoBrainer Imaging Centers, Inc. for CAD 0.51 million. Algernon Pharmaceuticals Inc. (CNSX:AGN) entered into share exchange agreement to acquire NoBrainer Imaging Centers, Inc. for CAD 0.45 million on May 12, 2025. Algernon Pharmaceuticals Inc. will issue (i) 4.5 million common shares and 9 million Common Share purchase warrants (each, a “Warrant”) to be issued on the closing date; and (ii) 0.45 million preferred shares to be issued on or before the date that is six (6) months from the Closing Date following approval of the creation of the Preferred Share class by Algernon Pharmaceuticals Inc.’s shareholders. Assuming the Algernon Pharmaceuticals receives shareholder approval, the Preferred Shares are convertible into, without payment of any consideration and without further action on the part of the holder thereoften (10) Common Shares. The Preferred Shares will include a ten (10) percent annual dividend payable in Common Shares or Preferred Shares at the discretion of the Algernon Pharmaceuticals's board of directors. If shareholder approval is not obtained, the Preferred Shares will be adjusted to Common Shares on a one (1) for ten (10) basis.
All NIC Shareholders shall enter into a voting support agreement in favour of Algernon Pharmaceuticals Inc. in respect of the consideration securities received in connection with the Transaction. The Transaction is subject to approval of the CSE and expects to close within five business days.
Algernon Pharmaceuticals Inc. (CNSX:AGN) completed the acquisition of NoBrainer Imaging Centers, Inc. for CAD 0.51 million on May 22, 2025. Under the terms of the agreement, final consideration paid by Algernon includes (i) 5.5 million common shares in the capital of the Algernon and 5.5 million Common Share purchase warrants; and (ii) 0.45 million preferred shares and 0.45 million Preferred Share purchase warrants to be issued on or before the end of six (6) months following approval of the creation of the Preferred Share class by the Algernon’s shareholders. Duyuru • Jan 06
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO for Repirinast in Kidney Disease Patent Algernon Pharmaceuticals Inc. announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/255,364 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast). The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has been issued corresponding patents in Japan and China, with applications pending in Europe and Canada. The Chronic Kidney Disease Market size is estimated at USD 84.85 billion in 2025, and is expected to reach USD 109.95 billion by 2030, at a CAGR of 5.32% during the forecast period (2025-2030). Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model.Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms. Preclinical DataData from the UUO study demonstrated that clinically relevant doses resulted in statistically significant improvements in the reduction in fibrosis as measured by Sirius Red staining over untreated controls: Telmisartan (3 mg/kg), a positive control, reduced fibrosis by 32.6% (p<0.001); Cenicriviroc (40 mg/kg) a CCR2/5 chemokine receptor antagonist with reported anti-fibrotic activity, reduced fibrosis by 31.9% (p=0.00032). Repirinast (90 mg/kg) reduced fibrosis by 50.6% (p<0.000001). Repirinast (30 mg/kg) reduced fibrosis by 20.8% (p>0.05). The combination of Repirinast (30 mg/kg) and telmisartan (3 mg/kg) reduced fibrosis by 54.2% (p<0.000001). In addition, the mass of the fibrotic kidney was lower than the negative control (p<0.001). Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name Romet™ for the treatment of Asthma. Romet™ was marketed for over 25 years in Japan. Mitsubishi discontinued manufacturing and sales of the drug in 2013. Accordingly, Algernon has retained Zhejiang Ausun Pharmaceutical in Zhejiang, China to manufacture a cGMP Repirinast supply. Mast cells are recruited to sites of cellular damage, and degranulation of mast cells leads to release of a myriad of proinflammatory chemical mediators which lead to tissue damage in a self-propagating cascade. NP-251 binds to receptors on mast cells and prevents their degranulation, which the Company believes could help prevent fibrosis in multiple organ classes including the kidneys. Duyuru • Aug 20
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding On August 20, 2024, Algernon Pharmaceuticals Inc closed the transaction. The Company paid cash finder’s fees totaling CAD 4,800 and issued 40,000 finders warrants to eligible finders for investors introduced to the Company by the eligible finder. Certain insiders of the Company participated in the Offering in the amount of CAD 60,000 Duyuru • Aug 08
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Algernon Pharmaceuticals Inc. announced a non-brokered private placement to issue 1,250,000 units at an issue price of CAD 0.12 per Unit for the gross proceeds of CAD 150,000 on August 7, 2024. Each Unit will consist of one Class A common share and one Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share at an exercise price of CAD 0.24 per Warrant Share for a period of 2 years from the date of issuance. The Offering is expected to close on August 15, 2024.The Company may pay cash finder’s fees and finders warrants to eligible finders, up to eight percent of the proceeds raised and units issued for investors introduced to the Company by the eligible finder. The securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. Duyuru • Aug 02
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.408 million in funding On August 2, 2024, Algernon Pharmaceuticals Inc. closed the transaction. The Company paid cash finder’s fees totaling CAD 5,376 and issued 44,800 finders warrants to eligible finders for investors introduced to the Company by the eligible finder. Certain insiders of the Company participated in the Offering in the amount of CAD 77,760. Duyuru • Jul 16
Algernon Pharmaceuticals Inc. Reports Results of Study Showing 93% Cough Suppression with Ifenprodil Algernon Pharmaceuticals Inc. reported that ifenprodil achieved a 93% (p = 0.036) reduction in median cough count in an acute guinea pig citric acid challenge study. The multi-dose study was conducted under the direction of Seyltx Inc. ("Seyltx"), a private US-based drug development company which recently acquired Algernon's ifenprodil research program for the purchase price of $2 million and a 20% equity position. The study was designed to inform dose selection in Seyltx's planned Phase 2b ifenprodil human study, recently named SILINDA, in refractory chronic cough ("RCC"). Seyltx has also announced that patient enrollment in the study is expected to begin in early 2025. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NR2B subunit, which prevents glutamate signalling. Ifenprodil represents a first-in-class potential treatment for chronic cough and interferes with central signalling in the brain, supressing the urge to cough. The near-complete suppression of cough was observed in animals receiving a dose of 30 mg/kg, in a dose-dependent manner, below the no observed adverse effect level dose ("NOAEL"). Other dosing arms included 1, 3, and 10 mg/kg. A clear and statistically significant dose response was observed. The full results of the study will be presented at the London International Cough Symposium July 18th - 19th, 2024. In an earlier Algernon Phase 2a clinical trial measuring cough in patients with idiopathic pulmonary fibrosis, ifenprodil, 20 mg TID (three times daily), reduced cough by ~40% from baseline (p = 0.001). In an earlier Algern on Phase 2a clinical trial measuring respiratory trial measuring cough in patients withidiopathic pulmonary fibrosis. Ifenprodil, 20 u mg TID (three times daily), reduced cough by approximately 40% from baseline (p= 0.001). SILINDA Phase 2b Study Summary: Based on U.S. FDA feedback, Seyltx’s SILINDA program is currently structured to include three dose arms and a placebo arm, evaluating the efficacy, safety, and tolerability of ifenprodil in approximately 240 adults with RCC. SILINDA will be placebo-controlled, parallel-arm trial randomized 1:1:1:1 with expected treatment arms of 40 mg TID, 80 mg TID, 120 mg TID, and placebo. The primary endpoint of 24-hour cough frequency will be measured at 12-weeks. The SILINDA Phase 2b program’s primary endpoint will be assessed using the VitaloJAK® cough monitoring system in a patient population that is not stratified for baseline 24-hour cough frequency given the uniform efficacy seen in the Phase 2a open label study across both low and high cough count patients. Key exploratory efficacy endpoints include the Cough Severity using Visual Analogue Scale (“CS-VAS”), the Leicester Cough Questionnaire (“LCQ”) and real-time longitudinal cough monitoring. Topline data from SILINDA are expected at the end of 2026. Duyuru • Jul 12
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.25 million in funding Algernon Pharmaceuticals Inc. announced a non-brokered private placement to issue 2,083,333 units at an issue price of CAD 0.12 per unit for the gross proceeds of CAD 249,999.96 on July 11, 2024. Each Unit will consist of one Class A common share and one Common Share purchase warrant Each Warrant will entitle the holder to acquire one Common Share at an exercise price of CAD 0.24 per Warrant Share for a period of 2 years from the date of issuance subject to acceleration of the Expiry Date as described below. The Offering is expected to close on July 20, 2024. The Company may pay cash finder’s fees and finders warrants to eligible finders, up to eight percent of the proceeds raised and units issued for investors introduced to the Company by the eligible finder. The securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. Duyuru • Apr 28
Algernon Pharmaceuticals Inc., Annual General Meeting, Jul 10, 2024 Algernon Pharmaceuticals Inc., Annual General Meeting, Jul 10, 2024. Duyuru • Apr 11
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding On April 10, 2024, Algernon Pharmaceuticals Inc. closed the transaction. Duyuru • Apr 03
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset Algernon Pharmaceuticals Inc. announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD 2 million cash and a 20% common share equity position in Seyltx, a U.S based private drug development company, on March 27, 2024. Seyltx plans to initiate an Ifenprodil multi-center Phase 2b placebo-controlled chronic cough study in CY2024. Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023. AGN Neuro has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2a DMT Stroke study. AGN Neuro is the world’s first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries. The Phase 2a human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke. Phase 2a Stroke Study Design: Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke. The decision to advance into a Phase 2 study was based on positive data from the Company’s Phase 1 trial conducted at the Centre for Human Drug Research (CHDR) in Leiden, Netherlands. This study showed that plasma levels of DMT associated with neuroplasticity in preclinical studies could be achieved with a prolonged, 6-hour infusion of DMT at a dose which did not cause a psychedelic experience. The amount given exceeded the human equivalent of the dose used in preclinical studies in rats which demonstrated neuroprotective effects. Duyuru • Jan 25
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis Algernon Pharmaceuticals Inc. announced that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF). The Company was previously granted a patent for the treatment of IPF in Canada and has also filed corresponding patent applications in the U.S., Europe, and China. Algernon's intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including those for novel salt forms, method of use, dosing and formulation. Duyuru • Dec 28
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding On December 27, 2023, Algernon Pharmaceuticals Inc. closed the transaction. The transaction included participation from certain insiders of the company for gross proceeds of CAD 173,505. The company paid cash finder’s fees totaling CAD 9,000 and issued 120,000 finders warrants to eligible finders for investors introduced to the company by the eligible finder. Duyuru • Dec 13
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Algernon Pharmaceuticals Inc. announced a non brokered private placement to issue 2,000,000 units at an issue price of CAD 0.075 per unit for the gross proceeds of CAD 150,000 on December 12, 2023. Each Unit will consist of one Class A common share and one Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share at an exercise price of CAD 0.20 per Warrant Share for a period of 2 years from the date of issuance, subject to acceleration of the Expiry Date as described below. The Offering is expected to close on December 20, 2023. The Company may pay cash finder’s fees and finders warrants to eligible finders, up to eight percent of the proceeds raised and units issued for investors introduced to the Company by the eligible finder. The securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. Duyuru • Nov 30
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD Algernon Pharmaceuticals Inc. announced that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast). The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company was recently issued patents for Repirinast in NASH from the U.S. and Japan, and has also filed corresponding patent applications in Canada and Europe. The company previously disclosed that Repirinast, in a widely used STAM™ mouse model of NASH from SMC Laboratories (Japan): Reduced hepatic fibrosis by 57% compared to vehicle (p < 0.0001); Reduced the NAFLD score, a composite histopathological measure of inflammation, steatosis and ballooning, by 31% compared to vehicle (3.125 vs 4.5 points, p = 0.059); In the same model, telmisartan, a positive control and the standard of care for NASH, reduced fibrosis by 27% (p = 0.014) Repirinast is also the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model. Because patients with NAFLD have a two-fold increased risk of CKD, even when controlling for other comorbidities such as obesity, type 2 diabetes mellitus and insulin resistance, Repirinast is a strong candidate for both indications. Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms. Duyuru • Jul 15
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding Algernon Pharmaceuticals Inc. announced a non-brokered private placement of 1,025,000 units at an issue price of CAD 0.20 per unit for the gross proceeds of CAD 205,000 on July 14, 2023. Each Unit will consist of one Class A common share and one Common Share purchase warrant. Each Warrant will entitle the holder to acquire one Common Share at an exercise price of CAD 0.25 per warrant share for a period of 2 years from the date of issuance. The securities will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. The transaction is expected to close on July 21, 2023. Duyuru • Feb 17
Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase Algernon Pharmaceuticals Inc. has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT"), a known psychedelic compound that is part of the tryptamine family. AGN Neuro also reported that the safety review committee has approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues. The trial is being conducted at the Centre for Human Drug Research ("CHDR") in Leiden, Netherlands. The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion for 6 hours, a duration that has never before been studied clinically. In addition, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will be recorded. Once the correct dose has been established in the first part of the study, the second part of the study will include dosing subjects for 6 hours, with repeated dosing over a two-week period. There will be up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naïve subjects. The Company has been working with its DMT and stroke experts from its medical advisory board to help design the planned Phase 2 studies of a sub-psychedelic dose of DMT in acute stroke and rehabilitation. The studies are expected to dose patients immediately following confirmation of their ischemic stroke diagnosis by imaging and will test the effects of DMT versus placebo on both the progress of the infarct and also on patients' recovery following the stroke. N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazon basin. DMT can also be synthesised in a laboratory. Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT), in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy. About Algernon NeuroScience Algernon NeuroScience is a private equity subsidiary of Algernon Pharmaceuticals and has been created to advance the Company's DMT stroke research program. AGN Neuro has filed a Form 1-A offering statement with the U.S. Securities and Exchange Commission, seeking qualification to raise up to USD 10 million for AGN Neuro by offering up to 37.5% of its common shares, (including the maximum amount of bonus shares) with majority ownership residing with AGN Pharma, under a Tier II Regulation A+ offering. Duyuru • Jan 12
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board Algernon Pharmaceuticals Inc. announce that it has appointed Dr. Peter Dicpinigaitis MD, Professor of Medicine at the Albert Einstein College of Medicine, in New York, as a medical consultant to the Company’s chronic cough research program. Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil). Dr. Dicpinigaitis is board-certified in Internal Medicine, Pulmonary Diseases and Critical Care Medicine. He is a faculty member of the Division of Critical Care Medicine at Montefiore Medical Center and is the founder and director of the Montefiore Cough Center, one of the few specialty centers in the world exclusively committed to the evaluation and management of patients with chronic cough. He received his undergraduate education at New York University (NYU) where he graduated summa cum laude with a degree in biochemistry. He obtained his medical degree from the NYU School of Medicine and remained at NYU-Bellevue for internal medicine residency training. He completed a fellowship in pulmonary & critical care medicine at the Mount Sinai Medical Center in New York, immediately after which he came to Einstein/Montefiore. In addition to experience in all aspects of clinical medicine within the spectrum of pulmonary and critical care, a major focus of Dr. Dicpinigaitis' clinical research for over 25 years has been in the area of cough. He has authored numerous peer-reviewed journal articles and book chapters on cough and is considered an authority on the performance of cough challenge studies in clinical research. He served as a co-author on cough management guidelines published by the American College of Chest Physicians as well as the European Respiratory Society and is the founder and chairman of the biannual American Cough Conference. Dr. Dicpinigaitis also serves as the Editor-in-Chief of the journal LUNG. Duyuru • Jan 10
Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Algernon Pharmaceuticals Inc. announced that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 for chronic cough to begin in third quarter of 2023. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signaling. Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough. The decision to advance the study is based on positive data previously reported on July 28, 2022, from the Company’s Phase 2a study of Idiopathic Pulmonary Fibrosis (IPF) and chronic cough, where Ifenprodil showed a significant improvement in mean objective 24-hour and waking cough counts in patients after 4 and 12 weeks. Patients with IPF are usually excluded from trials in refractory chronic cough, and cough in this population is regarded as extremely difficult to treat. The analysis showed that: The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks (p = 0.023) and 39.5% at 12 weeks (p = 0.001) compared to baseline The geometric mean awake cough counts were reduced by 30.2% at 4 weeks (p = 0.038) and 37.4% at 12 weeks (p = 0.002) compared to baseline Algernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough. The Company has since engaged in further discussions with the U.S. FDA, and plans to file an investigational new drug (IND) application shortly. While the Company originally planned to focus on IPF in a Phase 2b study, Algernon has now decided to pursue a chronic cough study first, and to delay planning its IPF Phase 2b study for Ifenprodil until a later date. Study Design The planned study design will include the following elements: Multinational, three-arm, randomized, double-blind, placebo-controlled trial to evaluate NP-120 in approximately 180 patients. Patients will be randomized 1:1:1 to receive NP-120 (20mg TID) or NP-120 (40mg TID), or placebo for 12 weeks. The primary endpoint will be the reduction in geometric mean 24-hr cough count over 12 weeks compared to placebo. Secondary endpoints will include safety, tolerability and patient-reported quality-of-life measures. 